DOCKET NO.: MOR-0277 PATENT

**Application No.:** 10/813,502

Office Action Dated: January 2, 2008

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:** 

1-69. (Canceled)

70. (Currently amended) A method for making a genetically stable cell that produces a

therapeutically hypermutated immunogen comprising the steps of:

introducing into a first cell that expresses a polynucleotidegene encoding a preselected

immunogen in vitro a polynucleotide comprising a nucleotide sequence encoding the first 133

amino acids of PMS2 comprising PMS2-134, wherein the expression product of the

polynucleotide comprising a nucleotide sequence encoding the first 133 amino acids of PMS2

is capable of inhibiting mismatch repair,

selecting cells that comprise a mutation in said polynucleotidegene encoding said preselected

immunogen, wherein the mutation results in enhanced antigenicity or immunogenicity of said

immunogen; and expressing a polynucleotide sequence of said mutated gene encoding said

preselected immunogen and comprising said mutation in a second cell, wherein said second

cell is genetically stable.

71. (Canceled)

72. (Currently amended) The method of claim 70 wherein said introduction of said

polynucleotide comprising a nucleotide sequence encoding the first 133 amino acids of PMS2

is in the presence of at least one DNA mutagen.

73. (Canceled)

74. (Currently amended) The method of claim 73 wherein the polynucleotide comprising

a nucleotide sequence encoding the first 133 amino acids of PMS2 comprises a truncation

mutation at codon 134.

DOCKET NO.: MOR-0277 PATENT

**Application No.:** 10/813,502

Office Action Dated: January 2, 2008

75. (Previously Presented) The method of claim 74 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type PMS2.

- 76. (Currently amended) The method of claim 70 wherein said step of selecting cells is based on a determination that the polynucleotide encoding said preselected immunogen comprises a mutation not present in said polynucleotide encoding said preselected immunogen as compared to the polynucleotide encoding said preselected immunogen of a parental cell-prior to introduction of the polynucleotide comprising a nucleotide sequence encoding the first 133 amino acids of PMS2 *PMS2-134*.
- 77. (Canceled)
- 78. (New) The method of claim 70 further comprising culturing said second cell.